Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 156

1.

Generation of bispecific IgG antibodies by structure-based design of an orthogonal Fab interface.

Lewis SM, Wu X, Pustilnik A, Sereno A, Huang F, Rick HL, Guntas G, Leaver-Fay A, Smith EM, Ho C, Hansen-Estruch C, Chamberlain AK, Truhlar SM, Conner EM, Atwell S, Kuhlman B, Demarest SJ.

Nat Biotechnol. 2014 Feb;32(2):191-8. doi: 10.1038/nbt.2797. Epub 2014 Jan 26.

PMID:
24463572
2.

Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies.

Schaefer W, Regula JT, Bähner M, Schanzer J, Croasdale R, Dürr H, Gassner C, Georges G, Kettenberger H, Imhof-Jung S, Schwaiger M, Stubenrauch KG, Sustmann C, Thomas M, Scheuer W, Klein C.

Proc Natl Acad Sci U S A. 2011 Jul 5;108(27):11187-92. doi: 10.1073/pnas.1019002108. Epub 2011 Jun 20.

3.

Protein design of IgG/TCR chimeras for the co-expression of Fab-like moieties within bispecific antibodies.

Wu X, Sereno AJ, Huang F, Zhang K, Batt M, Fitchett JR, He D, Rick HL, Conner EM, Demarest SJ.

MAbs. 2015;7(2):364-76. doi: 10.1080/19420862.2015.1007826.

4.

A novel glycoengineered bispecific antibody format for targeted inhibition of epidermal growth factor receptor (EGFR) and insulin-like growth factor receptor type I (IGF-1R) demonstrating unique molecular properties.

Schanzer JM, Wartha K, Croasdale R, Moser S, Künkele KP, Ries C, Scheuer W, Duerr H, Pompiati S, Pollman J, Stracke J, Lau W, Ries S, Brinkmann U, Klein C, Umana P.

J Biol Chem. 2014 Jul 4;289(27):18693-706. doi: 10.1074/jbc.M113.528109. Epub 2014 May 19.

5.

Generating bispecific human IgG1 and IgG2 antibodies from any antibody pair.

Strop P, Ho WH, Boustany LM, Abdiche YN, Lindquist KC, Farias SE, Rickert M, Appah CT, Pascua E, Radcliffe T, Sutton J, Chaparro-Riggers J, Chen W, Casas MG, Chin SM, Wong OK, Liu SH, Vergara G, Shelton D, Rajpal A, Pons J.

J Mol Biol. 2012 Jul 13;420(3):204-19. doi: 10.1016/j.jmb.2012.04.020. Epub 2012 Apr 25.

PMID:
22543237
6.

Bispecific antibodies with native chain structure.

Rouet R, Christ D.

Nat Biotechnol. 2014 Feb;32(2):136-7. doi: 10.1038/nbt.2812. No abstract available.

PMID:
24509759
7.

Therapeutic assessment of SEED: a new engineered antibody platform designed to generate mono- and bispecific antibodies.

Muda M, Gross AW, Dawson JP, He C, Kurosawa E, Schweickhardt R, Dugas M, Soloviev M, Bernhardt A, Fischer D, Wesolowski JS, Kelton C, Neuteboom B, Hock B.

Protein Eng Des Sel. 2011 May;24(5):447-54. doi: 10.1093/protein/gzq123.

PMID:
21498564
8.

SEEDbodies: fusion proteins based on strand-exchange engineered domain (SEED) CH3 heterodimers in an Fc analogue platform for asymmetric binders or immunofusions and bispecific antibodies.

Davis JH, Aperlo C, Li Y, Kurosawa E, Lan Y, Lo KM, Huston JS.

Protein Eng Des Sel. 2010 Apr;23(4):195-202. doi: 10.1093/protein/gzp094. Epub 2010 Feb 4.

PMID:
20299542
9.

Bispecific antibody derivatives based on full-length IgG formats.

Grote M, Haas AK, Klein C, Schaefer W, Brinkmann U.

Methods Mol Biol. 2012;901:247-63. doi: 10.1007/978-1-61779-931-0_16.

PMID:
22723106
10.

Progress in overcoming the chain association issue in bispecific heterodimeric IgG antibodies.

Klein C, Sustmann C, Thomas M, Stubenrauch K, Croasdale R, Schanzer J, Brinkmann U, Kettenberger H, Regula JT, Schaefer W.

MAbs. 2012 Nov-Dec;4(6):653-63. doi: 10.4161/mabs.21379. Epub 2012 Aug 27. Review.

11.

Generation of dual-variable-domain immunoglobulin molecules for dual-specific targeting.

Gu J, Ghayur T.

Methods Enzymol. 2012;502:25-41. doi: 10.1016/B978-0-12-416039-2.00002-1.

PMID:
22208980
12.

Controlled Fab-arm exchange for the generation of stable bispecific IgG1.

Labrijn AF, Meesters JI, Priem P, de Jong RN, van den Bremer ET, van Kampen MD, Gerritsen AF, Schuurman J, Parren PW.

Nat Protoc. 2014 Oct;9(10):2450-63. doi: 10.1038/nprot.2014.169. Epub 2014 Sep 25.

PMID:
25255089
13.

Synthesis of bifunctional antibodies for immunoassays.

DeSilva BS, Wilson GS.

Methods. 2000 Sep;22(1):33-43.

PMID:
11020315
14.

A modular IgG-scFv bispecific antibody topology.

Orcutt KD, Ackerman ME, Cieslewicz M, Quiroz E, Slusarczyk AL, Frangioni JV, Wittrup KD.

Protein Eng Des Sel. 2010 Apr;23(4):221-8. doi: 10.1093/protein/gzp077. Epub 2009 Dec 17.

15.

Anti-tumor activity of stability-engineered IgG-like bispecific antibodies targeting TRAIL-R2 and LTbetaR.

Michaelson JS, Demarest SJ, Miller B, Amatucci A, Snyder WB, Wu X, Huang F, Phan S, Gao S, Doern A, Farrington GK, Lugovskoy A, Joseph I, Bailly V, Wang X, Garber E, Browning J, Glaser SM.

MAbs. 2009 Mar-Apr;1(2):128-41. Epub 2009 Mar 11.

16.

LUZ-Y, a novel platform for the mammalian cell production of full-length IgG-bispecific antibodies.

Wranik BJ, Christensen EL, Schaefer G, Jackman JK, Vendel AC, Eaton D.

J Biol Chem. 2012 Dec 21;287(52):43331-9. doi: 10.1074/jbc.M112.397869. Epub 2012 Nov 1.

17.

Computationally Designed Bispecific Antibodies using Negative State Repertoires.

Leaver-Fay A, Froning KJ, Atwell S, Aldaz H, Pustilnik A, Lu F, Huang F, Yuan R, Hassanali S, Chamberlain AK, Fitchett JR, Demarest SJ, Kuhlman B.

Structure. 2016 Apr 5;24(4):641-51. doi: 10.1016/j.str.2016.02.013. Epub 2016 Mar 17.

PMID:
26996964
18.

Stability engineering of scFvs for the development of bispecific and multivalent antibodies.

Miller BR, Demarest SJ, Lugovskoy A, Huang F, Wu X, Snyder WB, Croner LJ, Wang N, Amatucci A, Michaelson JS, Glaser SM.

Protein Eng Des Sel. 2010 Jul;23(7):549-57. doi: 10.1093/protein/gzq028. Epub 2010 May 10.

PMID:
20457695
19.

PH1-derived bivalent bibodies and trivalent tribodies bind differentially to shed and tumour cell-associated MUC1.

Schoonooghe S, Burvenich I, Vervoort L, De Vos F, Mertens N, Grooten J.

Protein Eng Des Sel. 2010 Sep;23(9):721-8. doi: 10.1093/protein/gzq044. Epub 2010 Jul 8.

PMID:
20616115
20.

Fab-based bispecific antibody formats with robust biophysical properties and biological activity.

Wu X, Sereno AJ, Huang F, Lewis SM, Lieu RL, Weldon C, Torres C, Fine C, Batt MA, Fitchett JR, Glasebrook AL, Kuhlman B, Demarest SJ.

MAbs. 2015;7(3):470-82. doi: 10.1080/19420862.2015.1022694.

Supplemental Content

Support Center